Related Experiment Videos
Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP
J M De Klerk1, B A Zonnenberg, G H Blijham
1Department of Nuclear Medicine, University Hospital Utrecht, The Netherlands.
Anticancer Research
|May 1, 1997
Abstract:
Recent advances in radionuclide therapy offer a new approach for the management of metastatic bone pain. This paper reports the results of dosage escalation studies with 186Re-HEDP as a bone-seeking radiopharmaceutical in patients with bone metastases originating from breast or prostate cancer with regard to toxicity, pharmacokinetics and bone marrow dosimetry and the palliating effect on bone pain. Thrombocytopenia proved to be the dose limiting factor and 186Re-HEDP showed a considerable efficacy in end-stage patients with metastatic bone pain.